Cargando…
Macrophage AMPK β1 activation by PF-06409577 reduces the inflammatory response, cholesterol synthesis, and atherosclerosis in mice
Atherosclerotic cardiovascular disease is characterized by both chronic low-grade inflammation and dyslipidemia. The AMP-activated protein kinase (AMPK) inhibits cholesterol synthesis and dampens inflammation but whether pharmacological activation reduces atherosclerosis is equivocal. In the current...
Autores principales: | Day, Emily A., Townsend, Logan K., Rehal, Sonia, Batchuluun, Battsetseg, Wang, Dongdong, Morrow, Marisa R., Lu, Rachel, Lundenberg, Lucie, Lu, Jessie H., Desjardins, Eric M., Smith, Tyler K.T., Raphenya, Amogelang R., McArthur, Andrew G., Fullerton, Morgan D., Steinberg, Gregory R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654588/ https://www.ncbi.nlm.nih.gov/pubmed/38026185 http://dx.doi.org/10.1016/j.isci.2023.108269 |
Ejemplares similares
-
PF-06409577 Activates AMPK Signaling and Inhibits Osteosarcoma Cell Growth
por: Zhu, Yun-Rong, et al.
Publicado: (2021) -
Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models
por: Esquejo, Ryan M., et al.
Publicado: (2018) -
PF‐06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity
por: Su, Limin, et al.
Publicado: (2022) -
Lipogenesis inhibitors: therapeutic opportunities and challenges
por: Batchuluun, Battsetseg, et al.
Publicado: (2022) -
Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
por: Desjardins, Eric M., et al.
Publicado: (2023)